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The human microbiome has become a recognized factor in promoting and maintaining health.
We outline opportunities in interdisciplinary research, analytical rigor, standardization, and
policy development for this relatively new and rapidly developing field. Advances in these
aspects of the research community may in turn advance our understanding of human microbiome
biology.It is now widely recognized that distur-
bances in our normal microbial popula-
tions may be linked to acute infections
such as Clostridium difficile and to
chronic diseases such as heart disease,
cancer, obesity, and autoimmune disor-
ders (Clemente et al., 2012). This has
prompted substantial interest in the mi-
crobiome from both basic and clinical
perspectives. Although our genome is
relatively static throughout life, each of
our microbial communities changes pro-
foundly from infancy through adulthood,
continuing to adapt through ongoing ex-
posures to diet, drugs, and environment.
Understanding the microbiome and its
dynamic nature may be critical for diag-
nostics and, eventually, interventions
based on the microbiome itself. However,
several important challenges limit the abil-
ity of researchers to enter the microbiomefield and/or conduct research most
effectively.
Fundamental Challenges
Many microbiome studies to date have
focused on finding patterns, and moving
toward mechanism remains a major chal-
lenge. Once the ‘‘natural history’’ is better
characterized (research to date has
focused on a few locations in the Western
world, leaving much to be described), the
next step is to test for causality—when
cases and controls differ, does the micro-
biome cause the phenotypic change,
does the phenotype drive a change in
the microbiome, or are there feedback
loops between the two? Determining
which factors in a complex ecosystem
are most associated with important differ-
ences is necessary for the development of
diagnostic or therapeutic strategies. ForCell 15example, is the species membership,
gene functional profile, transcript or pro-
tein expression, metabolite profile, or a
combination thereof indicated in a partic-
ular condition? In this context, study
designs that allow causal inference such
as prospective longitudinal studies and
randomized, controlled experimental de-
signs are crucial.
Current microbiome studies tend to
take either top-down or bottom-up per-
spectives. The former constitute ecolog-
ical or systems-level investigations of
entire microbial communities, whereas
the latter focus on mechanistic examina-
tions of the effects of individual microbes,
genes, or metabolites. For example, ob-
servations of whole-community changes
associated with obesity are now quite
robust (Ley et al., 2005). The latter focuses
on a more detailed level, where several9, October 9, 2014 ª2014 Elsevier Inc. 227
representative studies have been very
successful in identifying microbial effects
in drug responses, such as the role of spe-
cific strains of the gut Actinobacterium
Eggerthella lenta in inactivating the car-
diac glycoside drug digoxin (Haiser
et al., 2013) and of p-cresol production
by certain gut bacteria interfering with
host detoxification of acetaminophen
(Clayton et al., 2009). The dynamic nature
of the microbiome thus requires scientific
approaches that incorporate aspects
both of genetics and of functional molec-
ular studies into the experimental design.
For example, integration of ecology with
molecular mechanism has identified gut
microbial metabolism as a potential
impediment in the use of therapeutic
food for treatment of severe malnutrition
in Malawi (Smith et al., 2013). Connecting
top-down and bottom-up strategies to
determine specific mechanism, as well
as patterns of association, is thus a key
goal for the field moving forward.
Assaying and Understanding the
Microbiome
Studies of the microbiome share, and in
some cases magnify, hurdles common
to many current omics fields. The cost of
sequencing is dropping much faster than
the cost of analysis, creating a bottleneck
in computation. Improved algorithms,
increased personnel trained in analysis
of microbiome data, and access to free
or inexpensive computing power such as
cloud-based resources would all help.
Other technical challenges are unique to
the study of microbial communities. For
example, because of the remarkable vari-
ation in the microbiome between body
sites, ages, locations, lifestyles, diets,
and host genetics, our definitions of
‘‘baseline’’ must continue to be expanded
to survey the worldwide microbiome in
health and its perturbations in disease.
This is true for all microbial components:
viruses, phage, eukaryotes, and archaea,
as well as bacteria.
Neither the data generation platforms
nor the analysis methods used with the
microbiome have yet reached the level
of refinement necessary for translational
applications and systematic meta-ana-
lyses, as has been achieved in other
omics areas such as gene expression or
genetics over many years of study. Unfor-
tunately, there are not as yet uniform stan-228 Cell 159, October 9, 2014 ª2014 Elseviedards for how data are deposited and
how experiments are described. Data
centralization efforts such as the NCBI
Short Read Archive (SRA), database of
Genotypes and Phenotypes (dbGaP),
and BioSample must balance extremely
broad accessibility—being all things to
all people—with the practical concerns
necessary to easily deposit and retrieve
individual studies’ files. The diversity and
lack of standards in human microbiome
research has resulted in little consistency
in how data are deposited in these repos-
itories, and many incompatible file for-
mats and conventions are currently in
use. Consequently, it is very difficult to
reconcile data from different studies,
even when the same phenotypes are
available. At the level of sequences
deposited within these resources, field-
specific considerations such as barcod-
ing and primers are not a part of the
overall repository design and may not be
described well in metadata, leading to
considerable challenges in interpretation.
The data set resulting from the Human
Microbiome Project (HMP) is one of the
largest such examples to date, where
the automated deposition pipelines of
multiple sequencing centers resulted in a
variety of files, some from resequencing
of the same sample and some containing
as few as a single read after human read
filtering (Human Microbiome Project Con-
sortium, 2012). For scientists who want to
use such data products for downstream
research, even large data sets from indi-
vidual projects thus pose a major data
integration challenge.
The microbiome of each subject exists
in a demographic, environmental, and
clinical context; the more precise the
definition of clinical phenotypes and natu-
ral history, the greater the analytic poten-
tial, particular in comparisons between
studies. Comparison of data and meta-
data between human microbiome studies
is also susceptible to batch effects (where
samples processed at the same time
appear to be different due to technical
variation) and other technical challenges.
Precise descriptions of phenotype, repro-
ducible study designs, and standardizing
sampling techniques are thus important
for assessing variability due to technical
effects, sampling bias, and other factors.
Standardization of phenotype and sam-
ple processing is of critical importance,r Inc.but the development of controlled vocab-
ularies (and tools to applying controlled
vocabularies) is not complete. One
ontology used with the microbiome,
EnvO, was originally developed for envi-
ronmental microbial communities and
only partially resolves these problems
(Hirschman et al., 2008); synonyms or
near synonyms are common, such as
‘‘stool,’’ ‘‘feces,’’ ‘‘faeces,’’ ‘‘gut,’’ etc.
Likewise, the gut has been annotated as
a ‘‘moist tropical environment’’ in some
data sets, but this is likely not the intended
biome description. Documentation sup-
porting the use of the MIxS standard for
the human microbiome community and
improved user interfaces for tools that
allow annotation and deposition of stan-
dards-compliant data could resolve a
major bottleneck in current studies (Yil-
maz et al., 2011). Similarly, the PhenX
project, which identifies a common set
of phenotype variables that are useful
across many studies (Pan et al., 2012),
provides a model for how microbiome
metadata could be annotated. Adherence
to the PhenX standard and to obtaining
BioSample identifiers that are stable
across multiple analyses of the same
specimen will be especially useful for
complex multiomic studies (Barrett et al.,
2012), as well as for systematic meta-
analysis of data sets where statistical
power is limited due to small population
sizes in individual studies. This is espe-
cially important if microbiome data are to
becomemore rapidly applicable in clinical
settings and in large-scale epidemiolog-
ical studies.
Human Studies Issues and Potential
Solutions
Particularly in the United States, many
opportunities exist to streamline micro-
biome research efforts among institutions
at the national level and for international
collaborations. For example, there are
significant duplications of effort and in-
consistencies resulting as individual mi-
crobiome researchers consult with their
local IRBs (Institutional Review Boards)
or other ethics committees in part
because microbiome studies are so new
and do not exactly fit the model of
either human genetics or microbiological
research. This is particularly true for
fecal microbiota transplantation, which
has been increasingly implemented into
clinical practice with neither clear regula-
tory guidelines nor a transparent facilita-
tion of the associated research opportu-
nities for making causal connections
between the microbiota and host physi-
ology. Efforts initiated by theNIH’sClinical
and Translational Science Award pro-
gram, such as IRBShare, may be particu-
larly applicable to the microbiome to
increase communication and sharing of
best practices between IRBs in multisite
studies. Registries designed to simplify
recruiting clinical research volunteers are
now common and provide the added
benefit of linking diverse projects across
a national research network (Richesson
and Vehik, 2010). As a research commu-
nity, we should consider systems such
as these to streamline subject recruitment
because they have been shown to in-
crease study enrollment and lower costs.
Methods used in combination with auto-
mated eligibility screening to identify clin-
ical participants could also be employed
to simplify recruitment (Beauharnais
et al., 2012; Pressler et al., 2012).
Privacy concerns unique to human-
associated microbial communities intro-
duce another challenge for microbiome
research. For example, in the HMP, the
identifier of the sequencing machine
generating each data set was access-
restricted because this seemingly innoc-
uous information could be associated
with a sequencing center and thus the
location of the donor individual (although
de minimis risk guidelines have since
been developed [Rhodes et al., 2011]).
Although consistency and streamlining
of IRBs is an ongoing effort in many fields,
there is as yet little understanding of
the subject protection ramifications of
releasing individual sets of host-associ-
ated microbial sequences. For many sub-
jects enrolled under earlier protocols, it is
often possible to release only aggregate
data, not detailed clinical information
that could theoretically be combined
with omics to allow the identification of in-
dividual subjects. dbGAP, the protected-
access database for sensitive biomedical
information (Mailman et al., 2007), plays
an important role but can be cumbersome
to work with due to regulatory compliance
and implementation complexity. The gen-
eration of large, free, and open IRB-
approved high-dimensional data sets will
lead to substantial advances across theboard, both in the human microbiome
and other areas of modern genomic
medicine.
Human microbiome studies are not
unique to any one NIH institute or center
(IC), and they are currently supported by
over a dozen ICs. This diversity in
research initiatives is exciting, but cultural
differences between ICs with respect to
data sharing, accessibility, and patient
confidentiality are a concern. A recently
formed Trans-NIH Microbiome Working
Group is expected to be especially valu-
able in harmonized policy development
between ICs, as well as in identifying
opportunities to that broaden access
to data and increase reusability of
results. Additional instruction to federal
grant review committees on the interpre-
tation and benefit of omics approaches
that complement traditional genetic ap-
proaches would also help advancemicro-
biome research, as would dedicated
study sections with members that span
the broad range of expertise required to
adequately assess such studies. Negoti-
ating interoperability within and across
the NIH and other federal agencies will
have a disproportionately large and
positive effect on microbiome research
because it will eliminate the need for a
large number of pairwise negotiations on
a case-by-case basis.
Prospects for the Future
Despite all the challenges, there is im-
mense potential for microbiome research.
Significant gains will be achieved with
modest investments in training, improved
submission tools, increased metadata
utilization, and resources such as stan-
dardized reagents, protocol registries or
reference data sets. Online tutorials with
example data, webinars, virtual machines
and packaged software encapsulating
data and methods for reproducibility,
and public computing environments
such as the DIAG [http://diagcomputing.
org]—which is specifically designed for
data-rich tasks such as those encoun-
tered in metagenomics—will all play
important roles. Experimental design
guidelines, adequate power calculations,
and basic improvements to data submis-
sion tools are critical, yet very difficult to
achieve in the current funding climate;
we must facilitate communication within
the human microbiome research commu-Cell 15nity to overcome this.Whenwe do, wewill
make it much easier for investigators at all
levels to enter the field and to propagate
standards and best practices within the
field.
Thus, although diverse microbial com-
munities inhabit many locations of our
bodies—and appear to be associated
with a spectrum of diseases—it will be
the organization of our communities of re-
searchers and funding agency program
managers that will ultimately improve hu-
man health. Practically speaking, stan-
dardization at every level will enhance
the application of both top-down and bot-
tom-up microbiome research. We believe
that, if the recommendations we propose
are implemented, the field will simulta-
neously be in a position to make efficient
use of existing resources, to consistently
design, execute, and share new study re-
sults, and to realize the full potential of
improved outcomes for a broad range of
human diseases.
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